Maximize the pricing and market access potential of your early pipeline
A top-10 pharmaceutical company sought to make informed decisions for an early pipeline product with little data available.
To guide early decision-making, it chose the PRMA Healthcheck® early module to provide a consistent approach to comparative assessment of market access risks and opportunities.
Our case study helps you to:
- understand how the organization was able to drive understanding and anticipation of the requirements of multiple payer archetypes
- appreciate how it identified the strengths and vulnerabilities in evidence generation plans and their implications
- recognize how cross-functional collaboration and integrated thinking across the organization was encouraged.